OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Operating Income

Last Annual Value

-6.81M

3-Year CAGR

-12%

5-Year CAGR

-313%

10-Year CAGR

-103%

OT

OS Therapies Incorporated Competitors Analysis of Operating Income

OSTX · NYSE
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-6.81M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
-18.23M
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
-13.28M
N/AN/AN/A
-87.98M
N/AN/AN/A
-26.55M
N/AN/AN/A
-10.54M
N/AN/AN/A
-60.68M
N/AN/AN/A
-36.51M
N/AN/AN/A
-13.04M
N/AN/AN/A
-16.22M
N/AN/AN/A
-67061.67B
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42